Dingdang Health Technology Group Ltd. has issued its proxy form and notice for the 2026 annual general meeting (AGM), set for 23 June 2026 at 2:00 p.m. in Beijing.
Key items on the agenda include:
1. FY 2025 Financial Results • Shareholders will vote on adopting the audited consolidated financial statements for the year ended 31 December 2025, together with reports from the board and Deloitte Touche Tohmatsu (external auditor).
2. Board Composition and Remuneration • Re-election of five directors: Executive Directors Mr Yang Yibin and Mr Meng Fanzhou; Non-executive Director Ms Li Chuheng; and Independent Non-executive Directors Mr Zhang Shouchuan and Mr Jiang Shan. • Authorisation for the board to determine directors’ remuneration.
3. Auditor Appointment • Proposal to re-appoint Deloitte Touche Tohmatsu as external auditor and authorise the board to fix its fees.
4. Share Capital Mandates • General mandate allowing the board to issue, allot and deal with new shares up to 20% of the company’s issued share capital (excluding treasury shares and shares repurchased but not yet cancelled) as at the passing date. • Repurchase mandate permitting buy-backs of up to 10% of issued shares on the same basis. • Extension of the issuance mandate by the volume of any shares repurchased under the above authorisation.
5. Corporate Governance Update • Special resolution to adopt the fifth amended and restated memorandum and articles of association, with authority delegated to any director to complete related formalities.
Proxy forms must be lodged with Computershare Hong Kong Investor Services by 2:00 p.m. on 21 June 2026. Shareholders submitting a proxy retain the right to attend and vote in person, with any earlier proxy deemed revoked upon such attendance.
Comments